anti-HLA-A*02:01/p53 R175H bispecific T-cell engager CLSP-1025

{
  "id": "MLC-T-ONC-010788",
  "term": "anti-HLA-A*02:01/p53 R175H bispecific T-cell engager CLSP-1025",
  "field": "Oncology and biomedicine",
  "definition": "An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176) bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific antigen CD3epsilon (CD3e), with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02:01/p53 R175H bispecific TCE CLSP-1025 specifically targets and binds to CD3 on cytotoxic T lymphocytes (CTLs) with its anti-CD3 domain and the p53(R175H)168-176 mutant peptide bound to HLA-A*02:01 expressed on tumor cells with its anti-peptide HLA (pHLA) domain. This activates and redirects CTLs to HLA-A*02:01/p53 R175H-expressing tumor cells, which results in the CTL-mediated cell death of these p53 R175H-expressing tumor cells. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.",
  "synonyms": [
    "anti-p53 R175H T-cell engager CLSP-1025",
    "anti-p53 R175H TCE CLSP-1025",
    "anti-p53 R175H/CD3 fusion protein CLSP-1025",
    "bispecific T-cell engager anti-HLA-A*02:01/p53 R175H CLSP-1025",
    "bispecific TCE CLSP-1025",
    "p53 R175H/HLA-A*02:01-specific T-cell engager CLSP-1025",
    "pHLAre (TM) CLSP-1025",
    "precise HLA redirecting engager CLSP-1025"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-hla-a-02-01-p53-r175h-bispecific-t-cell-engager-clsp-1025/"
}